维普中文期刊产品整合服务
194篇 您的检索式:作者名="Klonoff"
    题名 作者 年代 出处 被引量
1Continuous glucose monitoring: roadmap for 21st century diabetes therapy 显示文摘Klonoff DC 2005Diabetes Care2005,28,5:1
2Exenatide effects on diabe- tes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years显示文摘Klonoff DC Buse JB Nielsen LL 2008Curr Med Res Opin2008,24,1:1
3Exenatide effects on diabetes, obesity, cardiovascular risk fac tors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 显示文摘Klonoff DC Buse JB Nielsen LL 2008CmT Med Res Opin2008,24,:1
4Exenatide effects on dia- betes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 显示文摘Klonoff DC Buse JB Nielsen LL 2008Curt Med Res Opin2008,24,1:1
5Continuous glucose monitoring: an endocrine society clinical practice guideline 显示文摘Klonoff DC Buckingham B Christiansen JS 2011J Clin Endocrinol Metab2011,96,10:1
6Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic bio- markers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials显示文摘Buse JB Klonoff DC Nielsen LL 2007Clin Ther2007,29,1:1
7Continuousglucose monitoring: an endocrine society clinical practiceguideline 显示文摘Klonoff DC Buckingham B Christiansen JS 2011J Clin Endocrinol Metab2011,96,0:1
8Longterm outcome of head injuries:a 23-year follow up study of children with head injuries显示文摘Klonoff H Clark C Klonoff PS 1993J Neurol Neurosurg Psychiatry1993,56,4:1
9Metabolic effeets of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an inter- im analysis of data from the open-label, uncontrolled extension of three double-blind, plaoebo-eontrolled trials 显示文摘BUSE JB KLONOFF DC NIELSEN LL 2007Clin Ther2007,29,1:1
10Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 显示文摘KLONOFF D C BUSE J B NIELSEN L L 2008Curr Med Res Opin2008,24,1:1
11An economic analysis of interventions for diabetes显示文摘Klonoff DC Schwartz DM 2000Diabetes Care2000,23,3:1
12Continuous glucose monitoring:roadmap for 21st century diabetes therapy显示文摘Klonoff DC 2005Diabetes Care2005,28,5:1
13Exenatide effects on diabetes,obesity, cardiovascular risk factors and hepatic biomarkers in patientswith type 2 diabetes treated for at least 3 years*显示文摘KlonofF DC Buse JB Nielsen LL 2007Current MedicalResearch and Opinion?2007,24,1:1
14Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treaed for at least 3years显示文摘Klonoff DC Buse JB Nielsen LL 2008Curr Med Res Opin2008,24,1:1
15Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years显示文摘Klonoff D C Buse J B Nielsen L L 2008Curr Med Res Opin2008,24,1:1
16Continuous glucose monitoring:roadmap for 21st century diabetes therapy显示文摘Klonoff DC 2005Diabetes Care2005,28,:1
17Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years显示文摘Klonoff DC Buse JB Nielsen LL 2008Curr Med Res Opin2008,24,1:1
18Continuous glucose monitoring: roadmap for 21st century diabetes therapy 显示文摘Klonoff DC 2005Diabetes Care2005,28,5:1
19Continuous glucose monitoring:roadmapfor 21st century diabetes therapy 显示文摘Klonoff D C 2005Diabetes Care2005,28,5:1
20Continuous glucose monitoring:, roadmap for 21st century diabetes therapy显示文摘KLONOFF DC 2005Diabetes Care2005,28,:1
返回顶部 每页显示:
共10页 首页 上一页 第1页 下一页 末页 /10 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费